Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer
Conditions
Non-melanomatous Skin Cancer
Conditions: official terms
Carcinoma, Basal Cell - Skin Neoplasms
Conditions: Keywords
basal cell carcinoma of the skin, recurrent skin cancer
Study Type
Interventional
Study Phase
Phase 2
Study Design
Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: aminolevulinic acid hydrochloride
Type: Drug
Overall Status
Recruiting
Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment against skin cancer.

PURPOSE: This phase II trial is studying the side effects of photodynamic therapy using aminolevulinic acid and to see how well it works in treating patients with skin cancer.
Detailed Description
OBJECTIVES:

- To determine the safety and efficacy of intralesional photodynamic therapy using aminolevulinic acid and non-coherent blue light in patients with nodular basal cell carcinoma.

OUTLINE: Patients undergo photodynamic therapy comprising intralesional injection of aminolevulinic acid followed by non-coherent blue light therapy over approximately 17 minutes. Patients may undergo re-treatment with photodynamic therapy 8 weeks later.

Patients undergo photographic assessment of their skin lesions at baseline, 8 weeks, 16 weeks, and then at 1 and 2 years to evaluate healing time, clinical improvement, and side effects.

Patients undergo biopsies of their skin lesions at 16 weeks and then at 1 and 2 years to confirm histological clearance.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 30 Years
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Biopsy-proven basal cell carcinoma on the trunk or extremities

- Tumor size ≤ 2 cm in diameter

PATIENT CHARACTERISTICS:

- Willing and able to comply with all follow-up requirements

- Mentally competent

- No active, localized, or systemic infections

- Not immunocompromised

- No coagulation disorder

- No photosensitivity or allergy to sunlight

- Not pregnant or nursing

- No history of keloid formation

- No history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis

PRIOR CONCURRENT THERAPY:

- No prior gold therapy

- No prior radiotherapy to the trunk and extremities

- More than 24 months since prior oral retinoids (e.g., isotretinoin or acitretin) or photosensitizing drugs (e.g., Declomycin®)

- More than 1 year since prior collagen or other injections, Botox® injections, chemical peels, dermabrasion, or resurfacing procedures

- More than 1 month since prior topical retinoid therapy

- No concurrent aspirin or antioxidants

- No concurrent anticoagulation medications
Location
Laser and Skin Surgery Center of New York
New York, New York, United States
Status: Recruiting
Contact: Roy G. Geronemus, MD - 212-686-7306 - mail@laserskinsurgery.com
Start Date
February 2008
Sponsors
Laser and Skin Surgery Center of New York
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page